A Global Firm Built Over Generations on a Foundation of Client Service

A Business Founded on a Simple and Powerful Model

Lazard is one of the most respected names in global financial services, standing for excellence, integrity and innovation on behalf of clients.

Founded in 1848, today our mission remains the same: To provide sophisticated and differentiated advice and investment solutions, custom-tailored for our clients.  

View our 2025 Annual Letter to Shareholders to learn more about the continued transformation of our firm, grounded in our strategy of delivering contextual alpha to help clients navigate an increasingly complex landscape.

You can also read more about our future ambitions and long-term growth strategy in Lazard 2030: Beyond What the World Sees Today, a note from Lazard’s CEO and Chairman Peter Orszag.


Lazard stands for sophisticated, differentiated and custom-tailored advice that solves problems and creates solutions for our clients, complemented by a fundamentally-driven investment approach to asset management, delivered globally by extraordinarily talented people working together, and representing the highest standards of integrity.

Peter Orszag Smiling in Studio
Peter Orszag CEO and Chairman

Careers at Lazard

At Lazard, the individual matters. Our firm was built on the premise that a multicultural and diverse talent pool can serve a global clientele best.

Just as importantly, Lazard is a firm where you can come up with great ideas, and then apply them.

We have opportunities for talented individuals to grow and develop at every stage of their career.


Latest Transactions

May 18, 2026
United States

NextEra Energy and Dominion Energy to Combine, Creating the Worlds Largest Regulated Electric Utility Business and North Americas Premier Energy Infrastructure Platform Benefiting Customers

$420 Billion

May 14, 2026
United States

PowerGEM Secures Strategic Growth Investment from General Atlantic and Announces Acquisition of Telos Energy

Undisclosed

May 14, 2026
United States

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

$5.6 Billion

View All Transactions